These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21586354)

  • 21. Drug design strategies for targeting G-protein-coupled receptors.
    Klabunde T; Hessler G
    Chembiochem; 2002 Oct; 3(10):928-44. PubMed ID: 12362358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PREDICT modeling and in-silico screening for G-protein coupled receptors.
    Shacham S; Marantz Y; Bar-Haim S; Kalid O; Warshaviak D; Avisar N; Inbal B; Heifetz A; Fichman M; Topf M; Naor Z; Noiman S; Becker OM
    Proteins; 2004 Oct; 57(1):51-86. PubMed ID: 15326594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
    Cappellacci L; Franchetti P; Pasqualini M; Petrelli R; Vita P; Lavecchia A; Novellino E; Costa B; Martini C; Klotz KN; Grifantini M
    J Med Chem; 2005 Mar; 48(5):1550-62. PubMed ID: 15743197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. G-protein-coupled receptor-focused drug discovery using a target class platform approach.
    Heilker R; Wolff M; Tautermann CS; Bieler M
    Drug Discov Today; 2009 Mar; 14(5-6):231-40. PubMed ID: 19121411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling the 3D structure of GPCRs: advances and application to drug discovery.
    Becker OM; Shacham S; Marantz Y; Noiman S
    Curr Opin Drug Discov Devel; 2003 May; 6(3):353-61. PubMed ID: 12833668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms.
    Jespers W; Schiedel AC; Heitman LH; Cooke RM; Kleene L; van Westen GJP; Gloriam DE; Müller CE; Sotelo E; Gutiérrez-de-Terán H
    Trends Pharmacol Sci; 2018 Jan; 39(1):75-89. PubMed ID: 29203139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Dynamics Simulations of Adenosine Receptors: Advances, Applications and Trends.
    Al-Shar'i NA; Al-Balas QA
    Curr Pharm Des; 2019; 25(7):783-816. PubMed ID: 30834825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists.
    Kolb P; Phan K; Gao ZG; Marko AC; Sali A; Jacobson KA
    PLoS One; 2012; 7(11):e49910. PubMed ID: 23185482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-Based Rational Design of Adenosine Receptor Ligands.
    Gutiérrez-de-Terán H; Sallander J; Sotelo E
    Curr Top Med Chem; 2017; 17(1):40-58. PubMed ID: 27448653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Simulations and Drug Discovery of Adenosine Receptors.
    Wang J; Bhattarai A; Do HN; Akhter S; Miao Y
    Molecules; 2022 Mar; 27(7):. PubMed ID: 35408454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacophoric models and 3D QSAR studies of the adenosine receptor ligands.
    Tintori C; Manetti F; Botta M
    Curr Top Med Chem; 2010; 10(10):1019-35. PubMed ID: 20370655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Basis of Ligand Dissociation from G Protein-Coupled Receptors and Predicting Residence Time.
    Guo D; IJzerman AP
    Methods Mol Biol; 2018; 1705():197-206. PubMed ID: 29188564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based drug design for G protein-coupled receptors.
    Congreve M; Dias JM; Marshall FH
    Prog Med Chem; 2014; 53():1-63. PubMed ID: 24418607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioinformatics and mathematical modelling in the study of receptor-receptor interactions and receptor oligomerization: focus on adenosine receptors.
    Guidolin D; Ciruela F; Genedani S; Guescini M; Tortorella C; Albertin G; Fuxe K; Agnati LF
    Biochim Biophys Acta; 2011 May; 1808(5):1267-83. PubMed ID: 20888789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring Adenosine Receptor Ligands: Potential Role in the Treatment of Cardiovascular Diseases.
    Geldenhuys WJ; Hanif A; Yun J; Nayeem MA
    Molecules; 2017 Jun; 22(6):. PubMed ID: 28587166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.
    Jacobson KA
    J Med Chem; 2013 May; 56(10):3749-67. PubMed ID: 23597047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural insight into receptor-selectivity for lurasidone.
    Ichikawa O; Okazaki K; Nakahira H; Maruyama M; Nagata R; Tokuda K; Horisawa T; Yamazaki K
    Neurochem Int; 2012 Dec; 61(7):1133-43. PubMed ID: 22929996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-Based Design of Potent and Selective Ligands at the Four Adenosine Receptors.
    Jespers W; Oliveira A; Prieto-Díaz R; Majellaro M; Åqvist J; Sotelo E; Gutiérrez-de-Terán H
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29125553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenosine receptor neurobiology: overview.
    Chen JF; Lee CF; Chern Y
    Int Rev Neurobiol; 2014; 119():1-49. PubMed ID: 25175959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of receptor structure in determining adenosine receptor activity.
    Olah ME; Stiles GL
    Pharmacol Ther; 2000 Feb; 85(2):55-75. PubMed ID: 10722120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.